AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.